falimint
pronilide
Identification
| Name | falimint |
| CAS Number | 553-20-8 |
| FDA UNII | I26A23734J |
| Molecular Formula | C11 H14 N2 O4 |
| Molecular Weight | 238.24338000 |
| Nikkaji Number | J10.628C |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Soluble in | water, 481.1 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | information only not used for fragrances or flavors |
| Recommendation for falimint usage levels up to | not for fragrance use. |
| Recommendation for falimint flavor usage levels up to | not for flavor use. |
No supplier data available
Potential Uses
Natural Occurrence
Synonyms
acetamide, N-(5-nitro-2-propoxyphenyl)-
5'-
nitro-2'-propoxyacetanilide
N-(5-
nitro-2-propoxyphenyl)acetamide
pronilide
1-
propoxy-2-acetamino-2-nitrobenzol
PubMed:
[Homologs of 2-acetamino-4-nitropropoxybenzene (Falimint). 2. Metabolism of homologs].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 11. Plasma levels and urinary elimination in single and multiple administration].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropopoxybenzolum (Falimint). 10. Biotransformation of the active substance in chick embryo and in in vitro systems].
PubMed:
[The pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). Biotransformation of the agent in various animal species].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 8. Biotransformation of the active agents].
PubMed:
[Use of Falimint in the preparation of children for fibrogastroduodenoscopy].
PubMed:
[Pharmaceutic and biopharmaceutic assessment of acetylaminopropoxybenzolum (Falimint). 7. The buccal resorption of Falimint].
PubMed:
[The pharmaceutical and biopharmaceutical assessment of acetylaminonitropropoxybenzene (Falimint). 6. Quantitative composition of metabolites].
PubMed:
[Pharmaceutical and biopharmaceutical assessment of acetylaminopropoxybenzene (Falimint). 5. Characterization of metabolites of Falimint with square wave- and oscillopolarography].
PubMed:
[Pharmaceutic and biopharmaceutic evaluation of acetylaminonitropropoxybenzene (Falimint). A Biotransformation of the active agent].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 3: Polarographic analysis and determination of active agents].
PubMed:
[Use of falimint postoperatively in tonsillectomy].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). 2. Purity studies with a multi-stage phase solubility analysis and evaluation].
PubMed:
[Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). 1. Studies on the purity of active substances].